Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million;
Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023;
Q3 2024 Net loss improved by 6% compared to Q3 2023;
Conference Call and Webcast Today at 8:30 a.m. ET
LOUISVILLE, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2024.
“The Biodesix team is pleased to report another solid quarter focused on executing and delivering on our three main goals - driving revenue growth through the adoption of our lung diagnostic tests and biopharma services, continued implementation of operational efficiencies, and maintaining a cost-disciplined approach as we drive our business to profitability,” said Scott Hutton, CEO of Biodesix.
“We reported 40% year-over-year growth in lung diagnostics revenue, a growing book of biopharma services contracts, sustained gross margins in the high 70% range, and improved Net Loss on our path to profitability. In addition, at the annual meeting of the American College of Chest Physicians (CHEST), we presented new clinical data on our Nodify XL2® and Nodify CDT® tests, and announced a new clinical study (CLARIFY) to expand our data in diverse patient populations tested in a real-world clinical setting. Building on this momentum, we are reiterating our prior guidance of $70-$72 million for 2024 and we look forward to achieving Adjusted EBITDA profitability in the second half of 2025. At Biodesix, our tests play a vital role in treating the deadliest of all cancers. Our committed and driven team embraces the opportunity, and the responsibility, to transform the standard of care to improve outcomes for patients.”
Third Quarter Ended September 30, 2024 Business Highlights
- Grew Lung Diagnostic test volume to 13,900, a 34% improvement over the third quarter of 2023.
- Quarterly gross profit margin of 77.0% versus 76.1% for the third quarter of 2023.
- Presented compelling new data at the CHEST Annual Meeting and announced the launch of a new clinical study, CLARIFY.
- New data was presented detailing the experience of healthcare providers using the Nodify Lung® Nodule Risk Assessment Tests (Nodify XL2 and Nodify CDT tests) in over 35,000 patients tested in a real-world clinical setting. Results shared were consistent with prior studies, highlighting the high proportion of results that up- or down-classify patients into actionable risk categories with clear, guideline-recommended, diagnostic plans.
- The new study, CLARIFY, is designed to confirm performance of the Nodify CDT and Nodify XL2 tests in diverse patient subgroups through a retrospective chart review of up to 4,000 patients that were tested in a real-world clinical setting. The study’s intent is to expand the extensive evidence characterizing the validation and utility of Nodify Lung testing.
Third Quarter Ended September 30, 2024 Financial Highlights
- Total revenue of $18.2 million, an increase of 35% over the third quarter 2023:
- Lung Diagnostic revenue of $17.2 million reflected a year-over-year increase of 40% driven by the continued adoption of Nodify XL2 and Nodify CDT nodule risk assessment tests and strong reimbursement. However, test volumes were impacted at the end of the third quarter by disruption to patients, healthcare providers, and Biodesix teammates in the southeast due to Hurricane Helene;
- Biopharmaceutical Services revenue of $1.0 million decreased 17% year-over-year, driven by the timing of receipt of samples and shift of the completion of certain projects from the end of the third quarter into the beginning of the fourth;
- Third quarter 2024 gross profit of $14.0 million, or 77.0% gross margin compared to 76.1% gross margin in the comparable prior year period. Our steady margin performance is primarily driven by volume growth in Lung Diagnostic testing that continues to drive down the per test costs;
- Operating expenses (excluding direct costs and expenses) of $22.6 million, an increase of 29% as compared to the third quarter 2023, which includes $3.0 million of non-cash stock compensation expense and depreciation and amortization as compared to $1.7 million in third quarter of 2023. This increase is primarily attributable to an increase in sales and marketing costs to support both business lines’ sales growth to enhance product awareness and drive adoption, and an increase in depreciation expense related to the leasehold improvements in the Company’s Louisville, CO offices and laboratory which opened in January 2024;
- Net loss of $10.3 million, an improvement of 6% as compared to the same period of 2023;
- Adjusted EBITDA was a loss of $5.6 million, a slight increase over the loss of $5.4 million in the third quarter of 2023 and consistent with the second quarter of 2024;
- Cash and cash equivalents of $31.4 million as of September 30, 2024, a decrease from $42.2 million from June 30, 2024;
- Cash and cash equivalents as of September 30, 2024 includes the final milestone payment of $6.1 million for the acquisition of Integrated Diagnostics in 2018.
- Cash and cash equivalents as of September 30, 2024 includes the final milestone payment of $6.1 million for the acquisition of Integrated Diagnostics in 2018.
2024 - 2025 Financial Outlook
The Company is reiterating the 2024 revenue forecast of between $70 million and $72 million.
Conference call and webcast information
Listeners can register for the webcast via this link. Analysts who wish to participate in the question-and-answer session should use this link. A replay of the webcast will be available via the Company’s investor relations page on the website approximately two hours after the call’s conclusion. Participants are advised to join 15 minutes prior to the start time.
For a full list of Biodesix press releases and webinars, please visit biodesix.com.
About Biodesix
Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood-based IQLung™ test portfolio for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS® test, and the VeriStrat® test to support treatment decisions across all stages of lung cancer and expedite personalized treatment. In addition, Biodesix collaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information about Biodesix, visit biodesix.com.
Trademarks: Biodesix, Nodify Lung, Nodify XL2, Nodify CDT, IQLung, GeneStrat, GeneStrat NGS, and VeriStrat are trademarks or registered trademarks of Biodesix, Inc. The ddPCR technology is a trademark of Bio-Rad Laboratories, Inc.
Use of Non-GAAP Financial Measure
Biodesix reported results are presented in accordance with generally accepted accounting principles in the United States (GAAP). Biodesix has provided in this press release financial information that has not been prepared in accordance with GAAP. Biodesix uses the non-GAAP financial measure, Adjusted EBITDA, internally in analyzing its financial results and believes that use of this non-GAAP financial measure is useful to investors as an additional tool to evaluate ongoing operating results and trends and in comparing Biodesix financial results with other companies in its industry, many of which present similar non-GAAP financial measures. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with Biodesix financial statements prepared in accordance with GAAP. A reconciliation of Biodesix historical non-GAAP financial measure to the most directly comparable GAAP measure has been provided in the financial statement tables included in this press release, and investors are encouraged to review the reconciliation.
Adjusted EBITDA is a key performance measure that our management uses to assess our financial performance and is also used for internal planning and forecasting purposes. We believe that this non-GAAP financial measure is useful to investors and other interested parties in analyzing our financial performance because it provides a comparable overview of our operations across historical periods. In addition, we believe that providing Adjusted EBITDA, together with a reconciliation of Net loss to Adjusted EBITDA, helps investors make comparisons between our Company and other companies that may have different capital structures, different tax rates, and/or different forms of employee compensation.
Adjusted EBITDA is used by our management team as an additional measure of our performance for purposes of business decision-making, including managing expenditures. Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our financial results that may not be shown solely by period- to-period comparisons of Net loss or Loss from operations. Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items and may not be directly comparable to similarly titled metrics used by other companies.
We calculate Adjusted EBITDA as Net loss adjusted to exclude interest, income tax expense, if any, depreciation and amortization, share-based compensation expense, loss on debt extinguishments, net, COVID-19 revenue, COVID-19 direct costs and expenses, change in fair value of warrant liabilities, net, other income, net, and other non-recurring items. Non-recurring items are excluded as they are not representative of our underlying operating performance. We also exclude revenue and direct costs and expenses associated with COVID-19 because we believe that these revenues and expenses do not reflect expected future operating results as they do not represent our Lung Diagnostic and Biopharmaceutical Services business. Adjusted EBITDA should be viewed as a measure of operating performance that is a supplement to, and not a substitute for Loss from operations, Net loss, and other GAAP measures.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of backlog and the timing and assumptions regarding collection of revenues on projections, availability of funds and future capital including under the term loan facility, expectations regarding revenue and margin growth and its impact on profitability, and the impact of a pandemic, epidemic, or outbreak, including the COVID-19 pandemic, on Biodesix and its operations and financial performance. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company’s ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix most recent annual report on Form 10-K, filed March 1, 2024 or subsequent quarterly reports on Form 10-Q during 2024, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
Contacts:
Media:
Natalie St. Denis
natalie.stdenis@
biodesix.com
(720) 925-9285
Investors:
Chris Brinzey
chris.brinzey@
westwicke.com
(339) 970-2843
| Biodesix, Inc. Condensed Balance Sheets (unaudited) (in thousands, except share data) | ||||||||
| September 30, 2024 | December 31, 2023 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 31,406 | $ | 26,284 | ||||
| Accounts receivable, net of allowance for credit losses of $246 and $65 | 8,036 | 7,679 | ||||||
| Other current assets | 4,575 | 5,720 | ||||||
| Total current assets | 44,017 | 39,683 | ||||||
| Non-current assets | ||||||||
| Property and equipment, net | 28,683 | 27,867 | ||||||
| Intangible assets, net | 6,438 | 7,911 | ||||||
| Operating lease right-of-use assets | 1,918 | 1,745 | ||||||
| Goodwill | 15,031 | 15,031 | ||||||
| Other long-term assets | 6,656 | 6,859 | ||||||
| Total non-current assets | 58,726 | 59,413 | ||||||
| Total assets | $ | 102,743 | $ | 99,096 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 2,537 | $ | 2,929 | ||||
| Accrued liabilities | 8,553 | 7,710 | ||||||
| Deferred revenue | 676 | 324 | ||||||
| Current portion of operating lease liabilities | 624 | 252 | ||||||
| Current portion of contingent consideration | — | 21,857 | ||||||
| Current portion of notes payable | 29 | 51 | ||||||
| Other current liabilities | 544 | 293 | ||||||
| Total current liabilities | 12,963 | 33,416 | ||||||
| Non-current liabilities | ||||||||
| Long-term notes payable, net of current portion | 36,112 | 35,225 | ||||||
| Long-term operating lease liabilities | 25,191 | 25,163 | ||||||
| Other long-term liabilities | 620 | 712 | ||||||
| Total non-current liabilities | 61,923 | 61,100 | ||||||
| Total liabilities | 74,886 | 94,516 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity | ||||||||
| Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2024 and 2023) issued and outstanding | — | — | ||||||
| Common stock, $0.001 par value, 200,000,000 authorized; 145,465,941 (2024) and 96,235,883 (2023) shares issued and outstanding | 145 | 96 | ||||||
| Additional paid-in capital | 481,958 | 424,050 | ||||||
| Accumulated deficit | (454,246 | ) | (419,566 | ) | ||||
| Total stockholders’ equity | 27,857 | 4,580 | ||||||
| Total liabilities and stockholders’ equity | $ | 102,743 | $ | 99,096 | ||||
| Biodesix, Inc. Condensed Statements of Operations (unaudited) (in thousands, except per share data) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenues | ||||||||||||||||
| Diagnostic Testing revenue | $ | 17,168 | $ | 12,301 | $ | 47,503 | $ | 32,395 | ||||||||
| Biopharmaceutical Services and other revenue | 983 | 1,190 | 3,391 | 2,024 | ||||||||||||
| Total revenues | 18,151 | 13,491 | 50,894 | 34,419 | ||||||||||||
| Direct costs and expenses | 4,179 | 3,229 | 11,231 | 9,636 | ||||||||||||
| Research and development | 2,547 | 1,938 | 7,145 | 8,099 | ||||||||||||
| Sales, marketing, general and administrative | 20,016 | 15,496 | 60,232 | 51,136 | ||||||||||||
| Impairment loss on intangible assets | — | — | 135 | 20 | ||||||||||||
| Total operating expenses | 26,742 | 20,663 | 78,743 | 68,891 | ||||||||||||
| Loss from operations | (8,591 | ) | (7,172 | ) | (27,849 | ) | (34,472 | ) | ||||||||
| Other (expense) income: | ||||||||||||||||
| Interest expense | (2,041 | ) | (2,386 | ) | (6,506 | ) | (7,207 | ) | ||||||||
| Loss on extinguishment of liabilities | — | — | (248 | ) | — | |||||||||||
| Change in fair value of warrant liability, net | — | (1,393 | ) | — | (1,332 | ) | ||||||||||
| Other (expense) income, net | 374 | 2 | (77 | ) | 4 | |||||||||||
| Total other expense | (1,667 | ) | (3,777 | ) | (6,831 | ) | (8,535 | ) | ||||||||
| Net loss | $ | (10,258 | ) | $ | (10,949 | ) | $ | (34,680 | ) | $ | (43,007 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.07 | ) | $ | (0.14 | ) | $ | (0.28 | ) | $ | (0.55 | ) | ||||
| Weighted-average shares outstanding, basic and diluted | 146,296 | 79,709 | 123,634 | 78,672 | ||||||||||||
| Biodesix, Inc. Reconciliation of Net Loss to Adjusted EBITDA (unaudited) (in thousands) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net loss | $ | (10,258 | ) | $ | (10,949 | ) | $ | (34,680 | ) | $ | (43,007 | ) | |||
| Interest expense | 2,041 | 2,386 | 6,506 | 7,207 | |||||||||||
| Depreciation and amortization | 1,492 | 782 | 4,324 | 2,351 | |||||||||||
| Share-based compensation expense | 1,515 | 954 | 5,373 | 4,292 | |||||||||||
| Loss on extinguishment of liabilities | — | — | 248 | — | |||||||||||
| COVID-19 Revenue | — | — | — | (13 | ) | ||||||||||
| COVID-19 Direct costs and expenses | — | — | — | 1 | |||||||||||
| Change in fair value of warrant liability, net | — | 1,393 | — | 1,332 | |||||||||||
| Other expense (income), net | (374 | ) | (2 | ) | 77 | (4 | ) | ||||||||
| Adjusted EBITDA | $ | (5,584 | ) | $ | (5,436 | ) | $ | (18,152 | ) | $ | (27,841 | ) | |||
